Clinical trials · California
Moderately to Severely Active Crohns Disease clinical trials in California
We’re tracking 41 recruiting moderately to severely active crohns disease studies with a site in California — including Phase 1/Phase 2, Phase 2, Phase 2/Phase 3, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in California
- NCT06430801RecruitingPhase 3
Study of tulisokibart for moderate to severe Crohn's disease
This trial tests a new medicine called tulisokibart for people with moderate to severe Crohn's disease. The medicine may help reduce inflammation and improve symptoms. It is for those who have not had success with other treatments.
Anaheim, CaliforniaAges 16–80 - NCT06588855RecruitingPhase 3
Study of afimkibart for moderate to severe ulcerative colitis
This trial is testing a new medication called afimkibart (RO7790121) for people with moderate to severe ulcerative colitis. It aims to see if this treatment can help reduce inflammation and improve symptoms in people who haven't had success with other therapies.
Apple Valley, CaliforniaAges 16–80 - NCT06819891RecruitingPhase 3
Study of afimkibart for active Crohn's disease
This trial tests a new medicine called afimkibart for people with moderately to severely active Crohn's disease that has not responded well to other treatments. It aims to see if the medicine can safely reduce inflammation and improve symptoms.
Lancaster, CaliforniaAges 16–80 - NCT06819878RecruitingPhase 3
Afimkibart for moderate to severe Crohn's disease
This study tests an experimental drug called afimkibart for people with moderate to severe Crohn's disease who haven't responded well to other treatments. The goal is to see if the drug can help control symptoms and reduce inflammation over time.
Garden Grove, CaliforniaAges 16–80 - NCT07499232RecruitingPhase 3
Guselkumab vs Risankizumab for Crohn's disease
This trial compares two drugs, guselkumab and risankizumab, to see which works better for people with moderate-to-severe Crohn's disease. Both are given as injections and aim to reduce inflammation in the gut.
Anaheim, CaliforniaAges 18 years+ - NCT07577843RecruitingPhase 3
Testing JNJ-78934804 for moderate to severe Crohn's disease
This study tests a new drug called JNJ-78934804 for people with moderate to severe Crohn's disease who have not responded well to or can't tolerate current treatments. The goal is to see if this drug can reduce inflammation and symptoms in the digestive tract.
Anaheim, CaliforniaAges 18 years+ - NCT07196722RecruitingPhase 2/Phase 3
Testing icotrokinra for moderate to severe Crohn's disease
This study tests a new medicine called icotrokinra for people with moderate to severe Crohn's disease who have not responded well to other treatments. It aims to see if icotrokinra can help reduce symptoms and improve gut health.
Anaheim, CaliforniaAges 18 years+ - NCT07415044RecruitingPhase 2
Study of LY4268989 for moderate to severe ulcerative colitis
This study tests an investigational medication called LY4268989 for adults with moderate to severe ulcerative colitis (UC). It's for people who have tried other treatments without success. The goal is to see if the drug can reduce inflammation and improve symptoms.
Anaheim, CaliforniaAges 18–80 - NCT04779320RecruitingPhase 3
Vedolizumab for teens with moderate to severe Crohn's
This trial tests vedolizumab to treat children and teens with moderate to severe Crohn’s disease when standard treatments haven’t worked or caused side effects. It may help reduce gut inflammation and symptoms and help some patients stay healthier over time.
San Diego, CaliforniaAges 2–17 - NCT05923073RecruitingPhase 3
Guselkumab for children with active Crohn’s disease
This Phase 3 trial tests guselkumab to treat children with moderately to severely active Crohn’s disease and ongoing inflammation in the bowel. If you qualify, the study will check whether the medicine can improve symptoms and healing, especially in children who did not respond to other treatments.
Los Angeles, CaliforniaAges 2–17 - NCT05995353RecruitingPhase 3
Risankizumab for children with moderate to severe Crohn's
This study tests a new medicine called risankizumab for children with moderate to severe Crohn's disease. It is given as an IV infusion or a shot under the skin to see if it can reduce inflammation and improve symptoms.
Oakland, CaliforniaAges 2–17 - NCT06257706RecruitingPhase 4
Healing the bowel wall in Crohn's disease with vedolizumab
This study tests whether a medicine called vedolizumab can help heal all layers of the bowel wall in Crohn's disease. It uses a special ultrasound to see inside the bowel, aiming for deeper healing than usual.
Los Angeles, CaliforniaAges 18–80 - NCT06332534RecruitingPhase 3
Upadacitinib in children with moderate to severe Crohn's disease
This study tests an oral pill called upadacitinib for children with moderate to severe Crohn's disease that hasn't responded well to other treatments. It aims to see if the medicine can reduce inflammation and improve symptoms safely.
Oakland, CaliforniaAges 2–17 - NCT06456593RecruitingPhase 2
Obefazimod for moderate to severe Crohn's disease
This trial tests an experimental oral medication called obefazimod for people with moderate to severe Crohn's disease. It aims to see if the drug can reduce inflammation and improve symptoms when other treatments have not worked well.
Irvine, CaliforniaAges 18–75 - NCT06226883RecruitingPhase 2
Testing MORF-057 for moderate to severe Crohn's disease
This study tests an oral medicine called MORF-057 for people with moderate to severe Crohn's disease. It aims to see if the drug can reduce inflammation and improve symptoms for those who haven't had success with other treatments.
Lancaster, CaliforniaAges 18–85 - NCT06233461RecruitingPhase 2
A study of TAK-279 for Crohn's disease
This study tests an oral medication called TAK-279 to see if it can safely reduce inflammation in the bowel for people with moderate to severe Crohn's disease who haven't had success with other treatments.
Orange, CaliforniaAges 18–75 - NCT06721962RecruitingPhase 1/Phase 2
Testing an experimental treatment for moderate to severe Crohn's disease
This trial is testing a new investigational treatment called TRX103 for adults with moderate to severe Crohn's disease that has not responded to at least two other advanced therapies. The study aims to see if this treatment can reduce inflammation and improve symptoms.
Sacramento, CaliforniaAges 18–65 - NCT06937099RecruitingPhase 3
Testing two drugs for Crohn's with weight issues
This trial tests two study drugs, mirikizumab and tirzepatide, in people with moderate to severe Crohn's disease who also have overweight or obesity. The goal is to see if these treatments can help control Crohn's symptoms and inflammation.
Anaheim, CaliforniaAges 18–70 - NCT07184931RecruitingPhase 3
Testing duvakitug for active Crohn's disease
This study tests a new drug called duvakitug for people with moderately to severely active Crohn's disease who haven't responded well to other treatments. It aims to see if the drug can reduce symptoms and improve quality of life.
Valencia, CaliforniaAges 16–80 - NCT06045754RecruitingPhase 4
Study of vedolizumab with other drugs for Crohn's disease
This trial tests whether combining vedolizumab with adalimumab or ustekinumab helps people with moderate to severe Crohn's disease who haven't responded to other treatments. It aims to find better ways to manage symptoms and improve quality of life.
La Jolla, CaliforniaAges 18–70 - NCT05509777RecruitingPhase 3
Mirikizumab for children with active Crohn’s disease
This study tests mirikizumab to reduce inflammation and symptoms in children with Crohn’s disease that is currently active. It may help if your Crohn’s has not improved enough (or stopped working) with at least one other Crohn’s medicine.
Los Angeles, CaliforniaAges 2–17 - NCT06227910RecruitingPhase 3
Study of vedolizumab with or without upadacitinib for Crohn's disease
This trial tests combining two medicines, vedolizumab and upadacitinib, to see if they work better together than vedolizumab alone for people with moderate to severe Crohn's disease that hasn't responded well to other treatments.
Los Angeles, CaliforniaAges 18–65 - NCT06958536RecruitingPhase 2
Testing a new drug for moderate to severe Crohn's disease
This study tests an experimental drug called SAR442970 for people with moderate to severe Crohn's disease who haven't had success with standard treatments or biologics. The goal is to see if it can reduce inflammation and improve symptoms.
Escondido, CaliforniaAges 18–75 - NCT07483073RecruitingPhase 2
Study of new drugs for moderate to severe ulcerative colitis or Crohn's disease
This trial is testing multiple new drugs for people with moderate to severe ulcerative colitis or Crohn's disease who have not had success with at least one standard treatment. The goal is to find a better option that can help control symptoms and inflammation.
Los Angeles, CaliforniaAges 18–80
Moderately to Severely Active Crohns Disease trials by city in California
Where these studies are running in California
Institutions with a site for the recruiting moderately to severely active crohns disease studies listed above.
- Cedars-Sinai Medical Center · 6 studies
- Hoag Memorial Hospital Presbyterian · 6 studies
- Om Research LLC · 6 studies
- Clinnova Research · 5 studies
- Clinical Applications Laboratories · 4 studies
- Medical Associates Research Group, Inc. · 4 studies
- TLC Clinical Research Inc · 4 studies
- United Medical Doctors · 4 studies
What taking part in a moderately to severely active crohns disease study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Moderately to Severely Active Crohns Disease trials in other states
Common questions
- Are there moderately to severely active crohns disease clinical trials in California?
- Yes. We're currently tracking 41 recruiting moderately to severely active crohns disease studies with a site in California, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a moderately to severely active crohns disease study in California?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in California to take part?
- Not necessarily. These studies have a site in California, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a moderately to severely active crohns disease trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New moderately to severely active crohns disease studies open in California regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.